07:00 , Oct 20, 2014 |  BC Week In Review  |  Clinical News

Ameluz: Preliminary Phase III data

Preliminary data from a double-blind, German Phase III trial in 87 patients with mild to moderate actinic keratosis showed that a significantly greater proportion of patients who received a maximum of 2 treatments of Ameluz...
07:00 , Aug 18, 2014 |  BC Week In Review  |  Company News

Biofrontera sales and marketing update

Biofrontera launched Ameluz in Slovenia to treat actinic keratosis. The photodynamic therapy (PDT) consisting of nanoemulsion BF-200 with 5-aminolevulinic acid (ALA) photosensitizer followed by red light illumination is reimbursed by the Slovenian healthcare system. Biofrontera...
07:00 , Apr 9, 2012 |  BC Week In Review  |  Company News

Biofrontera, Bipharma B.V. deal

Biofrontera granted Bipharma exclusive rights to market actinic keratosis drug Ameluz ( BF-200 ALA ) in the Netherlands, Belgium and Luxembourg. Biofrontera will receive a €100,000 ($133,640) upfront payment, plus "a very significant share of...
08:00 , Jan 18, 2010 |  BioCentury  |  Finance

$104M Euro fund

BioMedPartners closed its BioMedInvest II fund at CHF106 million ($104.2 million). The fund will focus on private early- to mid-stage healthcare companies in Germany, Switzerland and neighboring European countries. BioMedPartners has over CHF250 million ($245.8...